A citation-based method for searching scientific literature

Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li, Chunling Liu, Yiping Zhang, Zhehai Wang, Yanping Hu, Kangsheng Gu, Jian'an Huang, Liangming Zhang, Jinlu Shan, Weiwei Ouyang, Yanqiu Zhao, Wu Zhuang, Yan Yu, Jun Zhao, Helong Zhang, Pei Lu, Weidong Li, Meimei Si, Mingjing Ge, Huaize Geng. Signal Transduct Target Ther 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
100


Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Samantha Wilkinson, Alind Gupta, Nicolas Scheuer, Eric Mackay, Paul Arora, Kristian Thorlund, Radek Wasiak, Joshua Ray, Sreeram Ramagopalan, Vivek Subbiah. JAMA Netw Open 2021
5
100

Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Jeng-Sen Tseng, Tsung-Ying Yang, Chih-Ying Wu, Wen-Hui Ku, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang. J Immunother 2018
20
100

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
164
100


Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
193
100


Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, Harry J M Groen, Heather Wakelee, Toyoaki Hida, Tony Mok, David Spigel, Enriqueta Felip, Makoto Nishio,[...]. J Clin Oncol 2016
240
100

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Chengwei Zhang, Xiao-Ran Han, Xiaobao Yang, Biao Jiang, Jing Liu, Yue Xiong, Jian Jin. Eur J Med Chem 2018
104
100

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
518
100


Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).
Chelsea E Powell, Yang Gao, Li Tan, Katherine A Donovan, Radosław P Nowak, Amanda Loehr, Magda Bahcall, Eric S Fischer, Pasi A Jänne, Rani E George,[...]. J Med Chem 2018
84
100

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gregory N Gan, Andrew J Weickhardt, Benjamin Scheier, Robert C Doebele, Laurie E Gaspar, Brian D Kavanagh, D Ross Camidge. Int J Radiat Oncol Biol Phys 2014
131
100

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta,[...]. N Engl J Med 2010
866
100

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
Fausto Petrelli, Chiara Lazzari, Raffaele Ardito, Karen Borgonovo, Alessandra Bulotta, Barbara Conti, Mary Cabiddu, Jody Filippo Capitanio, Matteo Brighenti, Mara Ghilardi,[...]. PLoS One 2018
25
100

Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
Dexter P Mendoza, Jessica J Lin, Marguerite M Rooney, Tianqi Chen, Lecia V Sequist, Alice T Shaw, Subba R Digumarthy. AJR Am J Roentgenol 2020
12
100

Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Chung Hyo Kang, Dong Ho Lee, Chong Ock Lee, Jae Du Ha, Chi Hoon Park, Jong Yeon Hwang. Biochem Biophys Res Commun 2018
56
100

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao,[...]. Target Oncol 2019
24
100

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
132
100

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Hiroyuki Yasuda, Lorena L de Figueiredo-Pontes, Susumu Kobayashi, Daniel B Costa. J Thorac Oncol 2012
111
100

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Mariacarmela Santarpia, Giuseppe Altavilla, Rafael Rosell. Expert Rev Respir Med 2015
23
100

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
Paola Bordi, Marcello Tiseo, Eleonora Rofi, Iacopo Petrini, Giuliana Restante, Romano Danesi, Marzia Del Re. Clin Lung Cancer 2017
37
100

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
100

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
55
100

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
633
100

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
Koh Furugaki, Naoki Harada, Yasushi Yoshimura. Anticancer Drugs 2022
1
100

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Zong-Jun Xia, Yin-Chun Ji, De-Qiao Sun, Xia Peng, Ying-Lei Gao, Yan-Fen Fang, Xing-Dong Zhao, Wei-Bo Wang, Jian Ding, Mei-Yu Geng,[...]. Acta Pharmacol Sin 2021
4
100


Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Yingming Wang, Lingfei Han, Fulei Liu, Fubai Yang, Xueyang Jiang, Haopeng Sun, Feng Feng, Jingwei Xue, Wenyuan Liu. Colloids Surf B Biointerfaces 2020
11
100

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Alice T Shaw, Luc Friboulet, Ignaty Leshchiner, Justin F Gainor, Simon Bergqvist, Alexei Brooun, Benjamin J Burke, Ya-Li Deng, Wei Liu, Leila Dardaei,[...]. N Engl J Med 2016
310
100

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Erin Larkins, Gideon M Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms,[...]. Clin Cancer Res 2016
50
100

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki. Cancer Cell 2011
434
100

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.
Joanna Roopkumar, Shyam K Poudel, Lorenzo Gervaso, Chandana A Reddy, Vamsidhar Velcheti, Nathan A Pennell, Keith R McCrae, Alok A Khorana. J Thromb Haemost 2021
11
100

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello. Crit Rev Oncol Hematol 2018
28
100

Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.
Jessica J Lin, Ginger Y Jiang, Nencyben Joshipura, Jennifer Ackil, Subba R Digumarthy, Sandra P Rincon, Beow Y Yeap, Justin F Gainor, Alice T Shaw. J Thorac Oncol 2019
21
100

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa,[...]. Cancer Sci 2020
19
100

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski,[...]. Cancer Discov 2018
142
100

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet,[...]. Lancet Oncol 2020
244
100

Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study.
Ziwei Huang, Qi Xiong, Zhi Cui, Haitao Tao, Sujie Zhang, Lijie Wang, Pengfei Cui, Shixue Chen, Di Huang, Bo Yang,[...]. Am J Transl Res 2021
4
100

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
229
100

Emerging Roles of ALK in Immunity and Insights for Immunotherapy.
Lan Wang, Vivian Wai Yan Lui. Cancers (Basel) 2020
7
100

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.
Koichi Ando, Kaho Akimoto, Hiroki Sato, Ryo Manabe, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori,[...]. Cancers (Basel) 2020
17
100

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, Hun Mi Choi, Kyoung-Ho Pyo, Seong Keun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim,[...]. Cancer Res 2018
18
100

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec,[...]. Clin Cancer Res 2020
57
100

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Richard Bayliss, Jene Choi, Dean A Fennell, Andrew M Fry, Mark W Richards. Cell Mol Life Sci 2016
55
100

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Ling Peng, Dafeng Lu, Yang Xia, Shaodong Hong, Giovanni Selvaggi, Justin Stebbing, Yilan Sun, Fei Liang. Front Oncol 2021
6
100

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.
Jin Kang, Xu-Chao Zhang, Hua-Jun Chen, Wen-Zhao Zhong, Yang Xu, Jian Su, Qing Zhou, Hai-Yan Tu, Zhen Wang, Chong-Rui Xu,[...]. Front Oncol 2020
7
100

The role of the ALK receptor in cancer biology.
B Hallberg, R H Palmer. Ann Oncol 2016
150
100

Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier. Cancer Chemother Pharmacol 2018
17
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.